Literature DB >> 26508201

Characteristics and prognosis of hepatocellular carcinoma detected in patients with chronic hepatitis C after the eradication of hepatitis C virus: A multicenter study from Japan.

Hidenori Toyoda1, Toshifumi Tada1, Kunihiko Tsuji2, Atsushi Hiraoka3, Yoshihiko Tachi4, Ei Itobayashi5, Koichi Takaguchi6, Tomonori Senoh6, Daichi Takizawa7, Toru Ishikawa8, Takashi Kumada1.   

Abstract

AIM: We investigated the characteristics and prognosis of patients with hepatocellular carcinoma (HCC) diagnosed after sustained virological response (SVR) to antiviral therapy for chronic hepatitis C virus (HCV) infection, namely, the eradication of HCV, according to surveillance status after SVR.
METHODS: In this multicenter study, liver function at HCC diagnosis and progression of HCC among patients with HCC diagnosed after SVR were compared. Outcomes were also investigated.
RESULTS: In patients not under surveillance after SVR, HCC was significantly more advanced at diagnosis, with tumors that were larger in size and of higher stage than in patients who continued under surveillance after SVR. Survival rates were significantly lower in patients not under surveillance (P < 0.0001). Among patients who were under surveillance, those with a 6-month surveillance interval had larger and higher stage HCC than patients with a 3-month interval. Recurrence rates in patients with a 6-month surveillance interval were significantly higher than in patients with a 3-month surveillance interval (P = 0.0417).
CONCLUSION: Lack of surveillance after SVR was obviously associated with more advanced HCC at detection, resulting in poor prognosis. More importantly, there may be a difference in the severity of HCC at diagnosis and prognosis based on the surveillance interval after SVR. Establishing guidelines how to survey patients with chronic hepatitis C after SVR is necessary.
© 2015 The Japan Society of Hepatology.

Entities:  

Keywords:  chronic hepatitis C; hepatocellular carcinoma; interval; prognosis; surveillance; sustained virological response

Year:  2015        PMID: 26508201     DOI: 10.1111/hepr.12613

Source DB:  PubMed          Journal:  Hepatol Res        ISSN: 1386-6346            Impact factor:   4.288


  7 in total

1.  Characteristics of hepatocellular carcinoma in patients with hepatitis C virus who received direct-acting antiviral therapy and achieved sustained virological response: The impact of a hepatologist on surveillance.

Authors:  Toshifumi Tada; Takashi Kumada; Tomomitsu Matono; Shinichiro Nakamura; Masahiko Sue; Yu Matsuo; Masahiro Takatani; Hiroko Iijima; Junko Tanaka
Journal:  JGH Open       Date:  2022-06-06

2.  Change in Fibrosis 4 Index as Predictor of High Risk of Incident Hepatocellular Carcinoma After Eradication of Hepatitis C Virus.

Authors:  Nobuharu Tamaki; Masayuki Kurosaki; Yutaka Yasui; Nami Mori; Keiji Tsuji; Chitomi Hasebe; Koji Joko; Takehiro Akahane; Koichiro Furuta; Haruhiko Kobashi; Hiroyuki Kimura; Hitoshi Yagisawa; Hiroyuki Marusawa; Masahiko Kondo; Yuji Kojima; Hideo Yoshida; Yasushi Uchida; Rohit Loomba; Namiki Izumi
Journal:  Clin Infect Dis       Date:  2021-11-02       Impact factor: 9.079

Review 3.  Chronic hepatitis C virus infection and pathogenesis of hepatocellular carcinoma.

Authors:  Simonetta Bandiera; C Billie Bian; Yujin Hoshida; Thomas F Baumert; Mirjam B Zeisel
Journal:  Curr Opin Virol       Date:  2016-10-11       Impact factor: 7.121

4.  Wisteria floribunda Agglutinin-Positive Mac-2 Binding Protein but not α-fetoprotein as a Long-Term Hepatocellular Carcinoma Predictor.

Authors:  Leona Osawa; Nobuharu Tamaki; Masayuki Kurosaki; Sakura Kirino; Keiya Watakabe; Wan Wang; Mao Okada; Takao Shimizu; Mayu Higuchi; Kenta Takaura; Hitomi Takada; Shun Kaneko; Yutaka Yasui; Kaoru Tsuchiya; Hiroyuki Nakanishi; Jun Itakura; Yuka Takahashi; Nobuyuki Enomoto; Namiki Izumi
Journal:  Int J Mol Sci       Date:  2020-05-21       Impact factor: 5.923

5.  Two Cases of Hepatocellular Carcinoma Arising Over 20 Years after a Sustained Virologic Response Following Interferon Therapy for Chronic Hepatitis C.

Authors:  Kazuhide Takata; Fuminori Ishii; Yotaro Uchida; Hiromi Fukuda; Ryo Yamauchi; Kaoru Umeda; Naoaki Tsuchiya; Takashi Tanaka; Keiji Yokoyama; Daisuke Morihara; Yasuaki Takeyama; Satoshi Shakado; Shotaro Sakisaka; Fumihito Hirai
Journal:  Intern Med       Date:  2020-04-30       Impact factor: 1.271

6.  Hepatocellular Carcinoma Risk Assessment for Patients With Advanced Fibrosis After Eradication of Hepatitis C Virus.

Authors:  Nobuharu Tamaki; Masayuki Kurosaki; Yutaka Yasui; Nami Mori; Keiji Tsuji; Chitomi Hasebe; Kouji Joko; Takehiro Akahane; Koichiro Furuta; Haruhiko Kobashi; Hiroyuki Kimura; Hitoshi Yagisawa; Hiroyuki Marusawa; Masahiko Kondo; Yuji Kojima; Hideo Yoshida; Yasushi Uchida; Toshifumi Tada; Shinichiro Nakamura; Satoshi Yasuda; Hidenori Toyoda; Rohit Loomba; Namiki Izumi
Journal:  Hepatol Commun       Date:  2021-10-22

7.  Liver stiffness measurement predicts hepatocellular carcinoma development in patients treated with direct-acting antivirals.

Authors:  Yoshihiko Tachi; Takanori Hirai; Yuko Kojima; Yoji Ishizu; Takashi Honda; Teiji Kuzuya; Kazuhiko Hayashi; Masatoshi Ishigami; Hidemi Goto
Journal:  JGH Open       Date:  2017-09-18
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.